Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Buprenorphine
Individualized optimal treatment regimes
Naltrexone
Opioid use disorder
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
26
05
2021
revised:
26
07
2021
accepted:
27
07
2021
pubmed:
18
9
2021
medline:
15
12
2021
entrez:
17
9
2021
Statut:
ppublish
Résumé
Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high. It is possible that optimally matching patients with medication type would reduce risk of relapse. Our objective was to learn a rule by which to assign type of medication for OUD to reduce risk of relapse, and to estimate the extent to which risk of relapse would be reduced if such a rule were used. This was a secondary analysis of an open-label randomized controlled, 24-week comparative effectiveness trial of injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days, or daily sublingual buprenorphine-naloxone (BUP-NX) for treating OUD, 2014-2017 (N = 570). Outcome was a binary indicator of relapse to regular opioid use during the 24 weeks of outpatient treatment. We found that applying an estimated individualized treatment rule-i.e., a rule that assigns patients with OUD to either XR-NTX or BUP-NX based on their individual characteristics in such a way that risk of relapse is minimized-would reduce risk of relapse by 24 weeks by 12% compared to randomly assigned treatment. The number-needed-to-treat with the estimated treatment rule to prevent a single relapse is 14. A simpler, alternative estimated rule in which homeless participants would be treated with XR-NTX and stably housed participants would be treated with BUP-NX performed similarly. These results provide an estimate of the amount by which a relatively simple change in clinical practice could be expected to improve prevention of OUD relapse.
Sections du résumé
BACKGROUND
Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high. It is possible that optimally matching patients with medication type would reduce risk of relapse. Our objective was to learn a rule by which to assign type of medication for OUD to reduce risk of relapse, and to estimate the extent to which risk of relapse would be reduced if such a rule were used.
METHODS
This was a secondary analysis of an open-label randomized controlled, 24-week comparative effectiveness trial of injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days, or daily sublingual buprenorphine-naloxone (BUP-NX) for treating OUD, 2014-2017 (N = 570). Outcome was a binary indicator of relapse to regular opioid use during the 24 weeks of outpatient treatment.
RESULTS
We found that applying an estimated individualized treatment rule-i.e., a rule that assigns patients with OUD to either XR-NTX or BUP-NX based on their individual characteristics in such a way that risk of relapse is minimized-would reduce risk of relapse by 24 weeks by 12% compared to randomly assigned treatment.
CONCLUSIONS
The number-needed-to-treat with the estimated treatment rule to prevent a single relapse is 14. A simpler, alternative estimated rule in which homeless participants would be treated with XR-NTX and stably housed participants would be treated with BUP-NX performed similarly. These results provide an estimate of the amount by which a relatively simple change in clinical practice could be expected to improve prevention of OUD relapse.
Identifiants
pubmed: 34534863
pii: S0376-8716(21)00526-3
doi: 10.1016/j.drugalcdep.2021.109031
pmc: PMC8595679
mid: NIHMS1741410
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Narcotic Antagonists
0
Buprenorphine
40D3SCR4GZ
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109031Subventions
Organisme : NIDA NIH HHS
ID : R00 DA042127
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Epidemiology. 2019 May;30(3):334-341
pubmed: 30789432
J Addict Med. 2017 Jan/Feb;11(1):63-69
pubmed: 27898496
J Am Stat Assoc. 2015;110(510):583-598
pubmed: 26236062
J Causal Inference. 2015 Mar;3(1):61-95
pubmed: 26236571
Int J Biostat. 2007;3(1):Article 4
pubmed: 22550646
Stat Med. 1997 Jan 15-Feb 15;16(1-3):285-319
pubmed: 9004398
Drug Alcohol Depend. 2015 May 1;150:112-9
pubmed: 25818060
Stat Appl Genet Mol Biol. 2007;6:Article25
pubmed: 17910531
Ann Stat. 2011 Apr 1;39(2):1180-1210
pubmed: 21666835
J Consult Clin Psychol. 2019 Oct;87(10):849-858
pubmed: 31556662
Stat. 2012 Jan 1;1(1):103-114
pubmed: 23645940
J Subst Abuse Treat. 2018 Aug;91:57-68
pubmed: 29910015
JAMA. 2014 May 14;311(18):1889-900
pubmed: 24825644
Contemp Clin Trials. 2016 Sep;50:253-64
pubmed: 27521809
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46
pubmed: 22065255
J Addict Med. 2020 Mar/Apr;14(2):95-98
pubmed: 31567596
Am J Psychiatry. 2021 Jul;178(7):660-671
pubmed: 34170188
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Addiction. 2016 Apr;111(4):695-705
pubmed: 26599131
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
JAMA Netw Open. 2020 Feb 5;3(2):e1921660
pubmed: 32083693
Contemp Clin Trials. 2016 Nov;51:34-43
pubmed: 27687743
Int J Biostat. 2016 May 1;12(1):305-32
pubmed: 27227726
Am J Addict. 2015 Jun;24(4):348-56
pubmed: 25659348
Ann Intern Med. 2020 Jan 7;172(1):35-45
pubmed: 31711134